Patent: 9,683,985

Summary for Patent: 9,683,985

Title:	Methods for assessing and identifying or evolving conditionally active therapeutic proteins
Abstract:	Methods for evolving or selecting or producing therapeutic proteins that exhibit reduced adverse side-effects and the resulting proteins are provided. For example, provided herein is an in vitro assay to identify conditionally active therapeutic proteins that exhibit better activity within one in vivo environment compared to another in vivo environment. The methods include the steps of a) testing the activity of a protein under conditions in which normal or increased activity is desired; b) testing the activity of the protein under conditions in which reduced activity compared to normal is desired; and c) comparing the activity in a) with b) and selecting/identifying a protein that has greater activity in a) compared to b). The selected/identified protein is a conditionally active protein.
Inventor(s):	Kodandapani; Lalitha (San Diego, CA), Bookbinder; Louis H. (San Diego, CA), Frost; Gregory I. (Del Mar, CA), Sheridan; Philip Lee (San Diego, CA), Shepard; Harold Michael (San Diego, CA), Wei; Ge (San Diego, CA), Huang; Lei (San Diego, CA)
Assignee:	Halozyme, Inc. (San Diego, CA)
Application Number:	13/200,666
Patent Claims:	see list of patent claims

Details for Patent 9,683,985

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-09-08
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2030-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-09-08